Abvc Biopharma (ABVC) Cash from Investing Activities (2010 - 2026)

Abvc Biopharma (ABVC) has 13 years of Cash from Investing Activities data on file, last reported at $47123.0 in Q1 2026.

• Quarterly Cash from Investing Activities changed N/A year-over-year to $47123.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$451063.0 (changed N/A YoY) and the FY2025 annual result came in at -$1.2 million, changed N/A from the prior year.
• Cash from Investing Activities rose to $47123.0 in Q1 2026, from -$29654.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $154173.0 in Q4 2023 to a low of -$1.5 million in Q3 2022.
• A 5-year average of -$209235.8 and a median of -$51719.0 in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 285.11% — and 2025, when it sank 1245.25%.
• Tracing ABVC's Cash from Investing Activities over 5 years: stood at -$83288.0 in 2022, then surged by 285.11% to $154173.0 in 2023, then plunged by 70.93% to $44825.0 in 2024, then plunged by 166.16% to -$29654.0 in 2025, then jumped by 258.91% to $47123.0 in 2026.
• The last three Cash from Investing Activities figures came in at $47123.0 (Q1 2026), -$29654.0 (Q4 2025), and -$513357.0 (Q3 2025), per Business Quant data.